BCM
SABS icon

Brookstone Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Brookstone Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,176
Closed -$17.4K – 908
2023
Q3 		$17.4K Hold
2,176
– – ﹤0.01% 819
2023
Q2 		$18.6K Hold
2,176
– – ﹤0.01% 816
2023
Q1 		$16.8K Hold
2,176
– – ﹤0.01% 817
2022
Q4 		$13.3K Buy
2,176
+529
+32% +$4.83K ﹤0.01% 809
2022
Q3 		$13K Sell
1,647
-315
-16% -$3.13K ﹤0.01% 776
2022
Q2 		$24K Buy
+1,962
New +$41.2K ﹤0.01% 749

Other funds holding SABS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brookstone Capital Management's SABS Position: Q4 2023 in Review

Brookstone Capital Management sold out of SAB Biotherapeutics (SABS) in Q4 2023, closing a stake of 2,176 shares — an estimated $17.4K sold.

Brookstone Capital Management first reported a position in SABS in Q2 2022 and held it in 6 quarters. The position peaked at $24K in Q2 2022. 42 funds tracked by Wall St. Rank hold SABS as of Q4 2023.

  • Brookstone Capital Management reported no remaining SAB Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Brookstone Capital Management sold 2,176 SAB Biotherapeutics shares in Q4 2023, an estimated $17.4K.
  • Brookstone Capital Management first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 6 quarters.
  • Brookstone Capital Management's SAB Biotherapeutics position peaked at $24K in Q2 2022.
  • 42 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2023.

Based on Brookstone Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.